Why the study?
What is the rationale for a risk-adapted treatment program investigating the role of full-dose ifosfamide-doxorubicin chemotherapy in pediatric nonrhabdomyosarcoma soft tissue sarcomas?
Population
Pediatric patients with nonrhabdomyosarcoma soft tissue sarcomas
Design
Review
Authors
Loading...
Does not yet alter pediatric NRSTS management; leaves open the role of risk-adapted ifosfamide-doxorubicin regimens for prospective trials.
What is the rationale for a risk-adapted treatment program investigating the role of full-dose ifosfamide-doxorubicin chemotherapy in pediatric nonrhabdomyosarcoma soft tissue sarcomas?
This review outlines the rationale for new prospective trials investigating risk-adapted chemotherapy regimens for pediatric nonrhabdomyosarcoma soft tissue sarcomas.
Ferrari et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: